Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505166 | 0.96 | GAA (0.60) | GAATSHRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3199685 | 0.90 | GAA (0.55) | GAATSHRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1505183 | 0.89 | GAA (0.56) | GAATSHRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1505156 | 0.87 | GAA (0.57) | GAATSHRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1505296 | 0.86 | KDM4E (0.58) | GAATSHRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1505168 | 0.85 | KDM4E (0.73) | GAATSHRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1505275 | 0.85 | PTPN11 (0.57) | GAATSHRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL26235402 | 0.84 | ALDH1A1 (0.54) | KDM4EALDH1A1SMN1; SMN2KMT2APTK2B | |
| SCHEMBL19859014 | 0.84 | TSHR (0.47) | GAATSHRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL11370707 | 0.84 | LMNA (0.49) | GAATSHRKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011027156-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2011-03-10 | — | — | WO | disclosed |
| US-20110059043-A1 | CHEMICAL COMPOUNDS | ARROW THERAPEUTICS LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059043-A1 | CHEMICAL COMPOUNDS | CYP2E1, CNR1, CYP3A5 | GAA 2290/4885TSHR 598/4885KDM4E 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.